Johnson & Johnson

144.67+0.2300+0.16%Vol 5.41M1Y Perf 9.92%
Sep 24th, 2020 16:00 DELAYED
BID144.60 ASK145.45
Open144.56 Previous Close144.44
Pre-Market- After-Market145.40
 - -%  0.73 0.50%
Target Price
165.77 
Analyst Rating
Moderate Buy 1.56
Potential %
14.58 
Finscreener Ranking
★+     45.10
Insiders Trans % 3/6/12 mo.
-100/-100/-60 
Value Ranking
★★+     49.22
Insiders Value % 3/6/12 mo.
-100/-100/-95 
Growth Ranking
★★★★     58.12
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-95 
Income Ranking
★★+     46.86
Market Cap380.89B 
Earnings Rating
Neutral
Price Range Ratio 52W %
74.23 
Earnings Date
13th Oct 2020

Today's Price Range

143.34145.25

52W Range

109.16157.00

5 Year PE Ratio Range

14.30310.40

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-3.02%
1 Month
-4.86%
3 Months
3.58%
6 Months
21.16%
1 Year
9.92%
3 Years
10.29%
5 Years
60.15%
10 Years
175.18%

TickerPriceChg.Chg.%
JNJ144.670.23000.16
AAPL108.221.10001.03
GOOG1 428.2913.08000.92
MSFT203.192.60001.30
XOM34.32-0.0700-0.20
WFC23.320.49002.15
FB249.530.51000.20
GE6.06-0.0500-0.82
JPM92.66-0.0800-0.09
Financial StrengthValueIndustryS&P 500US Markets
0.90
1.20
0.28
0.48
81.40
Leverage Ratio 2.60
ProfitabilityValueIndustryS&P 500US Markets
65.70
20.50
29.20
24.20
18.86
RevenueValueIndustryS&P 500US Markets
80.50B
30.58
2.96
3.27
DividendsValueIndustryS&P 500US Markets
2.71
4.04
5.07
5.69
Payout ratio59.00
Earnings HistoryEstimateReportedSurprise %
Q02 20201.501.6711.33
Q01 20202.032.3013.30
Q04 20191.861.881.08
Q03 20192.002.126.00
Q02 20192.422.586.61
Q01 20192.032.103.45
Q04 20181.951.971.03
Q03 20182.032.050.99
Earnings Per EndEstimateRevision %Trend
9/2020 QR1.98-2.46Negative
12/2020 QR1.90-4.04Negative
12/2020 FY7.852.21Positive
12/2021 FY8.94-2.30Negative
Next Report Date13th Oct 2020
Estimated EPS Next Report1.98
Estimates Count7
EPS Growth Next 5 Years %5.70
Volume Overview
Volume5.41M
Shares Outstanding2.63B
Trades Count68.26K
Dollar Volume940.39M
Avg. Volume8.41M
Avg. Weekly Volume7.59M
Avg. Monthly Volume6.40M
Avg. Quarterly Volume6.12M

Johnson & Johnson (NYSE: JNJ) stock closed at 144.67 per share at the end of the most recent trading day (a 0.16% change compared to the prior day closing price) with a volume of 5.61M shares and market capitalization of 380.89B. Is a component of S&P 500, Dow Jones 30, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 135100 people. Johnson & Johnson CEO is Alex Gorsky.

The one-year performance of Johnson & Johnson stock is 9.92%, while year-to-date (YTD) performance is -0.82%. JNJ stock has a five-year performance of 60.15%. Its 52-week range is between 109.16 and 157, which gives JNJ stock a 52-week price range ratio of 74.23%

Johnson & Johnson currently has a PE ratio of 26.20, a price-to-book (PB) ratio of 6.24, a price-to-sale (PS) ratio of 4.88, a price to cashflow ratio of 19.20, a PEG ratio of 2.32, a ROA of 9.69%, a ROC of 16.49% and a ROE of 24.54%. The company’s profit margin is 18.86%, its EBITDA margin is 29.20%, and its revenue ttm is $80.50 Billion , which makes it $30.58 revenue per share.

Of the last four earnings reports from Johnson & Johnson, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.98 for the next earnings report. Johnson & Johnson’s next earnings report date is 13th Oct 2020.

The consensus rating of Wall Street analysts for Johnson & Johnson is Moderate Buy (1.56), with a target price of $165.77, which is +14.58% compared to the current price. The earnings rating for Johnson & Johnson stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Johnson & Johnson has a dividend yield of 2.71% with a dividend per share of $4.04 and a payout ratio of 59.00%.

Johnson & Johnson has a Sell technical analysis rating based on Technical Indicators (ADX : 12.55, ATR14 : 2.89, CCI20 : -137.43, Chaikin Money Flow : -0.12, MACD : -1.21, Money Flow Index : 43.47, ROC : -3.36, RSI : 39.61, STOCH (14,3) : 21.01, STOCH RSI : 0.13, UO : 39.93, Williams %R : -78.99), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Johnson & Johnson in the last 12-months were: Alex Gorsky (Option Excercise at a value of $0), Ashley McEvoy (Option Excercise at a value of $0), Ashley McEvoy (Sold 29 000 shares of value $4 276 630 ), Hubert Joly (Buy at a value of $706 399), Jennifer L. Taubert (Option Excercise at a value of $0), Joaquin Duato (Option Excercise at a value of $0), Joseph J. Wolk (Option Excercise at a value of $0), Kathryn E. Wengel (Option Excercise at a value of $1 153 628), Kathryn E. Wengel (Sold 18 132 shares of value $2 758 475 ), Kathy Wengel (Option Excercise at a value of $126 305), Kathy Wengel (Sold 2 017 shares of value $284 538 ), Michael E. Sneed (Option Excercise at a value of $3 639 975), Michael E. Sneed (Sold 58 128 shares of value $8 683 568 ), Michael H. Ullmann (Option Excercise at a value of $0), Michael Sneed (Option Excercise at a value of $3 639 975), Michael Sneed (Sold 58 128 shares of value $8 683 568 ), Paulus Stoffels (Option Excercise at a value of $0), Peter M. Fasolo (Option Excercise at a value of $0), Robert J. Decker (Option Excercise at a value of $0), Thibaut Mongon (Option Excercise at a value of $1 738 618), Thibaut Mongon (Sold 39 224 shares of value $5 803 583 ), William D. Perez (Buy at a value of $63 843)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (68.75 %)
11 (68.75 %)
10 (66.67 %)
Moderate Buy
1 (6.25 %)
1 (6.25 %)
1 (6.67 %)
Hold
4 (25.00 %)
4 (25.00 %)
4 (26.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.56
Moderate Buy
1.56
Moderate Buy
1.60

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, close to half of total revenue is generated in the United States.

CEO: Alex Gorsky

Teplephone: +1 732 524-0400

Address: One Johnson & Johnson Plaza, New Brunswick 08933, NJ, USA

Number of employees: 135 100

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

54%46%

Bearish Bullish

49%52%

News

Stocktwits